SIRs for second neoplasms, according to length of follow-up
| Type of cancer . | Length of follow-up . | |||
|---|---|---|---|---|
| 0-5 y . | 6-10 y . | 11-15 y . | More than 15 y . | |
| No. of patients | 3 905 | 3 007 | 1 761 | 156 |
| Person-years of observation | 11 218 | 19 953 | 21 340 | 2 371 |
| All second cancers4-150 | ||||
| Observed | 35 | 18 | 8 | 0 |
| Observed:expected (95% CI) | 20.6 (5.8-28) | 6.1 (3.6-9.3) | 2.3 (1.0-4.3) | — |
| Solid tumors4-150,4-151 | ||||
| Observed | 14 | 16 | 7 | 0 |
| Observed:expected (95% CI) | 12.7 (6.9-20.3) | 8.9 (5.1-13.8) | 3.3 (1.3-6.3) | — |
| Leukemia | ||||
| Observed | 13 | 3 | 0 | 0 |
| Observed:expected (95% CI) | 233.9 (137.9-350.5) | 31.6 (5.9-77.4) | — | — |
| Lymphoma | ||||
| Observed | 4 | 0 | 1 | 0 |
| Observed:expected (95% CI) | 20.0 (5.2-44.4) | — | — | — |
| CNS tumors4-150 | ||||
| Observed | 4 | 11 | 2 | 0 |
| Observed:expected (95% CI) | 10.8 (2.8-24) | 17.5 (8.7-29.3) | 3.2 (0.3-9.1) | — |
| Type of cancer . | Length of follow-up . | |||
|---|---|---|---|---|
| 0-5 y . | 6-10 y . | 11-15 y . | More than 15 y . | |
| No. of patients | 3 905 | 3 007 | 1 761 | 156 |
| Person-years of observation | 11 218 | 19 953 | 21 340 | 2 371 |
| All second cancers4-150 | ||||
| Observed | 35 | 18 | 8 | 0 |
| Observed:expected (95% CI) | 20.6 (5.8-28) | 6.1 (3.6-9.3) | 2.3 (1.0-4.3) | — |
| Solid tumors4-150,4-151 | ||||
| Observed | 14 | 16 | 7 | 0 |
| Observed:expected (95% CI) | 12.7 (6.9-20.3) | 8.9 (5.1-13.8) | 3.3 (1.3-6.3) | — |
| Leukemia | ||||
| Observed | 13 | 3 | 0 | 0 |
| Observed:expected (95% CI) | 233.9 (137.9-350.5) | 31.6 (5.9-77.4) | — | — |
| Lymphoma | ||||
| Observed | 4 | 0 | 1 | 0 |
| Observed:expected (95% CI) | 20.0 (5.2-44.4) | — | — | — |
| CNS tumors4-150 | ||||
| Observed | 4 | 11 | 2 | 0 |
| Observed:expected (95% CI) | 10.8 (2.8-24) | 17.5 (8.7-29.3) | 3.2 (0.3-9.1) | — |